CymaBay Therapeutics announces MBX-8025 has received EMA PRIority MEdicines designation
CymaBay Therapeutics announced that MBX-8025 has been granted PRIority MEdicine designation by the EMA for treatment of primary biliary cholangitis in patients who do not tolerate or respond to ursodeoxycholic acid or do not respond to combination UDCA / obeticholic acid treatment. October 20, 2016